Funding Awarded
- Effects of tumor energetics on anti-tumor immunity through vasculature remodeling awarded by The G. Harold and Leila Y. Mathers Foundation. Principal Investigator. 2025-2028
- Mechanisms of "fragile" intratumoral regulatory T cells supporting anti-tumor immunity awarded by Cancer Research Institute, Inc. Principal Investigator. 2025-2027
- MALT1 as a rational therapeutic target in African American ancestry patients with DLBCL awarded by National Cancer Institute Principal Investigator. 2025-2026
- CD36 in breast cancer awarded by Pilatus Biosciences Inc Principal Investigator. 2025-2026
- SPORE: Adressing Health Disparities in Lymphoma awarded by National Cancer Institute. Co-investigator. 2025-2030
- Investigating the tumor metabolism-hypoxia-vasculature axis in the response of TNBC to immunotherapy Giorgia Colombo, Principal Investigator 2024 - 2026
- Elucidating the Role of the Tumor Suppressor KEAP1 in Antitumor Immunity awarded by National Cancer Institute. Co-investigstor. 2025-2026
- Prostate Cancer Non-Neuroendocrine Lineage Plasticity: Detection Using Multimodal Integration And immunotherapeutic Targeting awarded by Starr Cancer Consortium. Principal Investigator. 2024-2026
- Targeting MALT1 to Enhance Anti-Lymphoma Immunity and Response to Immunotherapy awarded by National Cancer Institute Roberta Zappasodi, Principal Investigator 2023 - 2028
- Tumor-metabolism-driven therapies to overcome TNBC immune resistance awarded by Breast Cancer Alliance Inc. Roberta Zappasodi, Principal Investigator 2023 - 2025
- Targeting Unmet Needs For B-cell Lymphomas awarded by Leukemia & Lymphoma Society, Inc. Roberta Zappasodi, Co-Investigator 2022 - 2027
- Restoring lymphoma immunosurveillance by combined EZH2 inhibition and immunotherapy. awarded by Leukemia & Lymphoma Society, Inc. Roberta Zappasodi, Principal Investigator 2021 - 2024
- SRA with BMS awarded by Bristol-Myers Squibb Company Principal Investigator 2021 - 2024
- Image-guided Trp-IDO/TDO-Kyn-AHR pathway inhibition, combined with immunotherapy awarded by National Cancer Institute Inna Serganova, Co-Investigator 2022 - 2026
- Exploiting tumor metabolism to optimize T cell therapy awarded by National Cancer Institute Inna Serganova, Principal Investigator 2021 - 2024
- SRA with BMS awarded by Bristol-Myers Squibb Company Roberta Zappasodi & Inna Serganova, Principal Investigators 2021 - 2024
